Dr. Reid is a serial entrepreneur and a startup CEO. He founded three public companies (VRTY:NASDAQ, ELOQ:NASDAQ, GNOM:NASDAQ) including Complete Genomics, the world’s second largest DNA sequencing company (behind Illumina). After Complete Genomics he founded Travera, a functional precision oncology testing company. Dr. Reid is an expert at launching and growing organizations that bring new technologies into commercial practice. He is now the CEO of Cancer Commons, his first nonprofit company. Cancer Commons helps late-stage cancers patients find new treatments. Under his leadership, Cancer Commons is launching a functional precision oncology clinical study that will evaluate the predictive accuracies of the available functional tests in selecting off-guideline cancer drugs for cancer patients who are out of options. Dr. Reid is a member of the Massachusetts Institute of Technology Corporation Development Committee. He is a scientific advisor to NGD, a bacterial genomics company, and to Adeste Therapeutics, a startup drug development company. He earned a BS in Physics from MIT, an MBA from the Harvard Business School, and a PhD in Management Science and Engineering from Stanford University.